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Structured Abstracts Required  
for Clinical Trials Published in the  
Journal of Investigative Dermatology
abstracts are the most-read element of any scientific report (Pitkin and Branagan, 1998), yet they do not always 
convey the full message revealed in the body of 
a publication. As an example of this, Hopewell 
et al. (2008) noted that a physician in Africa 
unwittingly altered an effective perinatal HIV-
prevention program to a less effective one 
solely on the basis of information provided in 
an abstract. The full text revealed weaknesses, 
including small sample size and incomplete 
data, and the results were unlikely to be appli-
cable to a physician’s situation; ultimately, the 
decision to alter practice based entirely on the 
abstract’s conclusions may have resulted in 
increased perinatal HIV transmission. Although 
it is unfortunate that this physician did not have 
access to full reports, the example nevertheless 
illustrates the potential human cost of mislead-
ing abstracts.
Mounting evidence indicates that the qual-
ity and completeness of information included 
in structured abstracts are superior to that of 
traditional (unstructured) abstracts, at least for 
clinical studies. Taddio et al. (1994) compared 
the quality of 300 structured and unstructured 
abstracts published in the British Medical 
Journal, the Canadian Medical Association 
Journal, and the Journal of the American 
Medical Association in the 1980s (nonstructured 
abstracts) and 1990s (structured abstracts). The 
overall mean quality scores for nonstructured 
and structured abstracts were 0.57 and 0.74, 
respectively (P < 0.001). Study purpose, set-
ting, number of dropouts, interventions, study 
variables, appropriate numeric and statistical 
values, and conclusions were especially poorly 
reported in unstructured abstracts. The same 
study, repeated 10 years later, indicated a sus-
tained improvement in the quality of structured 
versus unstructured abstracts (Wong et al., 
2005). Investigators in smaller specialties have 
documented similar improvements in abstract 
quality after instituting structured abstracts 
(Sharma and Harrison, 2006). Despite ini-
tial skepticism about the value of structured 
abstracts, Dupuy et al. (2003) showed that the 
quality of structured abstracts was consider-
ably higher than that of unstructured abstracts 
in three dermatology journals published in 
2000 and called for structured abstract report-
ing to be more widely adopted in dermatology 
journals. It is also worth mentioning that some 
leading journals use abstracts to make quick 
decisions on content suitability for submitted 
manuscripts, so it pays to get the abstract right 
(Groves and Abbassi, 2004).
JID was an early adopter of clinical trial reg-
istration (Williams and Stern, 2005) and adher-
ence to the CONSORT (Consolidated Standards 
of Reporting Trials) guidelines (Williams and 
Goldsmith, 2006), and it has established robust 
editorial procedures to ensure that these report-
ing standards are followed. In line with good 
reporting practice, JID will now require clinical 
trial reports to have structured abstracts, begin-
ning with submissions made after January 1, 
2011 and guidance on what to include will be 
added to our Instructions to Authors. There are 
two good reasons for limiting this requirement 
to reports of clinical trials. The first is that the 
work on structured abstracts for basic science 
is still under development. The second is that 
the CONSORT group has recently extended its 
guidance (Table 1) on what should be includ-
ed in a structured abstract on clinical trials 
(Hopewell et al., 2008).
Although JID does not publish many clinical 
trials, those that are published are well report-
ed. It is our hope that those who read abstracts 
of clinical trials published in JID will be able 
to understand exactly what was done to whom 
and with what outcome.
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Further information on good reporting of health research 
studies may be found at the EQUATOR website (http://www.
equator-network.org).
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table 1. items to include when reporting randomized trials in journal or conference abstracts
item description
Title Identification of the study as randomized
Authors1 Contact details for the corresponding author
Trial design Description of the trial design (e.g., parallel, cluster, noninferiority)
Methods
 Participants Eligibility criteria for participants and the settings where the data were collected
 Interventions Interventions intended for each group
 Objective Specific objective or hypothesis
 Outcome Clearly defined primary outcome for this report
 Randomization How participants were allocated to interventions
 Blinding Whether participants, caregivers, and those assessing the outcomes (masking) were blinded to group assignment
Results
 Numbers randomized Number of participants randomized to each group
 Recruitment Trial status
 Numbers analyzed Number of participants analyzed in each group
 Outcome For the primary outcome, a result for each group and the estimated effect size and its precision
 Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
1For conference abstracts.
Reprinted from Hopewell et al. (2008) with kind permission from the authors and The Lancet.
